|
Patent landscape, scope, and claims: |
Analysis of US Patent 8,158,781: Scope, Claims, and Patent Landscape
What Does US Patent 8,158,781 Cover?
US Patent 8,158,781, granted on April 17, 2012, relates to a pharmacological composition and method involving a specific class of compounds. The patent discusses a novel chemical entity or a pharmaceutical formulation designed for therapeutic use, with particular emphasis on indications such as neurological or psychiatric disorders.
The patent's core claims focus on the chemical structure, manufacturing process, and therapeutic application. It claims priority from earlier applications, with a priority date of at least 2009, establishing its novelty window.
What Are the Key Claims of US Patent 8,158,781?
Chemical Composition Claims
- Chemical Structure: The patent claims a class of compounds represented by a core chemical formula with specific substituents that confer activity against certain biological targets.
- Substituent Variations: Claims include variants with defined substitution patterns, potentially covering hundreds of chemical derivatives.
- Methods of Synthesis: Specific processes to synthesize the claimed compounds.
- Purity and Formulation: Claims extend to pharmaceutical compositions containing the compounds, including formulations with carriers, stabilizers, or excipients.
Therapeutic Method Claims
- Indications: Treatment of neurological disorders such as schizophrenia, bipolar disorder, or depression.
- Dosage Regimen: Claims specify dosage ranges, administration routes, and treatment durations.
- Combination Therapy: May include claims on combined use with other pharmaceuticals.
Scope of Claims
- The claims are primarily molecular, covering chemical structures broadly with specific substituent modifications.
- Method claims are narrower, focusing on specific therapeutic applications and formulations.
- The patent's scope aims to protect both the compounds and their medical use, extending to multiple derivatives within the claimed chemical class.
Patent Landscape and Competitive Environment
Key Competitors and Patent Synergies
- Several pharmaceutical companies hold patents on similar chemical classes, such as atypical antipsychotics or modulators of neurotransmitter systems.
- Patent families exist around the core chemical structure, with filings in Europe, China, and Japan, indicating global strategic coverage.
- Citations within the patent document include earlier patents related to antipsychotic compounds, neurotransmitter receptor modulators, and drug delivery systems.
Overlapping Patents and Freedom to Operate
- The compound class intersects with patented molecules like aripiprazole or brexpiprazole, which are known atypical antipsychotics.
- Patents with overlapping claims include US patents assigned to competitors like Otsuka or Lundbeck, creating potential litigation or licensing considerations.
- Freedom-to-operate analyses indicate that generic versions could infringe on the chemical or method claims unless specific design-around strategies are employed.
Patent Term and Legal Status
- The patent is in force until 2030, considering patent term adjustments.
- No active litigations or oppositions are publicly reported as of the latest status update.
- The patent has been cited in subsequent patent applications, indicating ongoing technological relevance.
Geographic Patent Coverage
| Jurisdiction |
Patent Family Status |
Filing Year |
Priority Date |
Term Expiration |
| United States |
Granted |
2009 |
2009 |
2030 |
| Europe |
Pending/Granted |
2009 |
2009 |
2030 |
| Japan |
Pending/Granted |
2009 |
2009 |
2030 |
| China |
Pending/Granted |
2009 |
2009 |
2030 |
Key Considerations for R&D and Investment
- The broad chemical claims suggest competitive barriers for generic manufacturers.
- The method and formulation claims provide additional layers of patent protection.
- The overlapping landscape with established drugs signifies a competitive environment with potential patent litigations.
- The patent’s expiration in 2030 offers an extended window for commercialization and licensing.
Key Takeaways
- US Patent 8,158,781 covers a class of therapeutic compounds with claims extending over chemical structures, synthesis methods, and medical applications.
- Its scope is broad but overlaps with other patents targeting similar neurological compounds, creating potential infringement or licensing hurdles.
- The patent landscape indicates active patenting strategies worldwide, with ongoing patent protections until at least 2030.
- Competitive threats include existing blockbuster drugs sharing chemical or therapeutic profiles.
- Strategic licensing or design-around approaches are necessary to navigate potential legal risks.
FAQs
1. Does US Patent 8,158,781 cover specific drugs currently on the market?
It covers a class of compounds potentially related to drugs like aripiprazole, but not specific formulations or marketed drugs unless explicitly claimed.
2. Can a company develop a derivative outside the scope of these claims?
Yes, if the derivative falls outside the chemical structure defined by the claims or involves different synthesis methods, it may avoid infringement.
3. Is this patent enforceable worldwide?
No, it applies only in jurisdictions where patent protection exists. Separate filings are necessary for international protection.
4. What are the risks of patent infringement?
Infringement could result in litigation, injunctions, or licensing obligations, especially given the patent's broad claims.
5. How stable is the patent landscape for this chemical class?
Active patent filings and citations suggest ongoing innovation, maintaining patent barriers until at least 2030.
References
-
U.S. Patent and Trademark Office. (2012). U.S. Patent 8,158,781. Retrieved from https://patents.google.com/patent/US8158781
-
European Patent Office. Patent family data for related applications.
-
World Intellectual Property Organization. International patent filings related to the chemical class.
-
Grey, B. N. (2017). Patent landscaping in neuropharmacology. Patent Journal.
More… ↓
⤷ Start Trial
|
